Kidney Infection Market Research Report Information By Diagnosis (Dipstick Urine Test, Imaging Test, Treatment (Medication, Antibiotics, Nsaids, Dialysis, Kidney Transplant), End User (Hospitals & Clinics, Nephrology Center, Research Institutes) - Forecast till 2030

Kidney Infection Market Scenario

The kidney infection market is projected to reach USD 9,401.42 Million by 2030 at 12.50% CAGR during the forecast period 2022-2030.Kidney infection is a result of infection in the bladder that spreads to the kidney. Most common bacteria causing kidney infection is E. coli. Kidney infections are very common, especially, an aging population. The blood test is performed to make sure that the kidneys are functioning normally. The urine test, called a urinalysis, detects any abnormal cells or proteins that relate to a kidney problem. If the blood and urine tests are normal, then no other tests are required. In some cases, these infections are diagnosed when a person undergoes an ultrasound examination or CT scan of the abdomen for some other reason. Additionally, the urologist may suggest an X-ray examination called “Voiding Cystourethrogram”.

Increasing prevalence of kidney infections, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the kidney infection market. Furthermore, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases are likely to fuel the kidney infection market growth during the forecast period. Moreover, increasing geriatric population is projected to boost the kidney infection market growth. Established market players in the developed countries lead the globalization by pushing new products and services into the developing countries and emerging economies. However, higher treatment cost may hinder the kidney infection market growth over the review period.

As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Kidney disease is often referred to as a “silent disease” as there are no symptoms in its early stages and can go undetected. Chronic kidney disease (CKD) is a global health burden risk factor for cardiovascular disease (CVD). High blood pressure and diabetes are the main causes of CKD. The high economic cost to health systems and decreased productivity are the major drawbacks of kidney diseases. NIDDK also stated that the overall prevalence of Chronic Kidney Disease (CKD) in the general population is approximately 14%. It also stated that in 2013, Medicare spending for patients with CKD aged 65 and older exceeded USD 50 billion, which accounted for 20% of total Medicare spending in this age group. Over 70% of the Medicare spending for CKD patients aged 65 and older was incurred by those who also had diabetes, congestive heart failure, or both.

Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation

Intended Audience

• Pharmaceutical and Biotechnological Companies


• Research and Development (R&D) Companies


• 
  Ambulatory Care Centers


• Academic Institutes and Universities


• Market Research and Consulting Service Providers


• Potential Investors

Segmentations

The kidney infection market is segmented on the basis of diagnosis, treatment, and end user.

On the basis of the diagnosis, kidney infection market is segmented into dipstick urine test and imaging test. The imaging test is further segmented into ultrasound, CT scan, voiding cystourethrogram, and others.

The treatment segment is divided into medication, dialysis, kidney transplant, and others. The medication is further segmented into antibiotics, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Based on the end user, kidney infection market is segmented into hospitals & clinics, nephrology center, research institutes, and others.

Regional Analysis

The Americas dominate the kidney infection market owing to the availability of technologically advanced medical devices for diagnosis and treatment of kidney infection such as dialysis machine, increasing patient population for a kidney infection, increasing government support for research & development, and high health care spending. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the kidney infection market in this region.   

The European region is exhibiting flourishing growth owing to the increasing emphasis on the development of new drugs, rising government support for research & development, and availability of funds for research. Rising number of specialty services offered by various healthcare providers in Europe also accelerate the growth of the kidney infection market. For instance, developed economies such as Germany and France are increasing investment in the healthcare domain and are focusing more on the hospital infrastructure.  

The Asia Pacific is the fastest growing kidney infection market owing to the presence of rapidly developing healthcare technology and high healthcare expenditure. Moreover, increasing patient population in countries such as India is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may speed up the market growth in this region.    

However, the Middle East & Africa holds the least share of the kidney infection market due to less availability of funds, limited medical facilities, and unavailability technologically advanced medical devices.

Figure: Kidney Infection Market, By Region Market Share, 2016 (%)

Key Players

AbbVie, Inc. (U.S.), Allergan plc. (U.K), Amgen Inc. (U.S.), AstraZeneca (U.K), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc. (U.K), Johnson & Johnson Services Inc. (U.S.), Keryx Biopharmaceuticals, Inc. (U.S.), Kissei Pharmaceutical Co. Ltd. (Japan), Pfizer (U.S.), Sanofi (France), Teva Pharmaceutical Industries Ltd. (Japan), and others.